| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Enzymes and Protein Markers |
1
Novadex, Inc., San Diego, CA 92121.
2
University of California–San Diego Medical Center,
Division of Rheumatology, San Diego, CA 92103.
3
University of Nebraska Medical Center, Department
of Internal Medicine, Omaha, NE 68198.
4
Metra Biosystems, Inc., 265 N. Whisman Rd.,
Mountain View, CA 94043.
a Author for correspondence. Fax 650-903-9500; e-mail jvisor{at}metrabio.com.
Chondrex, a major secretory protein of human chondrocytes and synovial fibroblasts, is increased in serum of patients with joint and cartilage disease. We have developed a sandwich-type ELISA for quantifying chondrex in serum. The interassay CVs were 2.8–3.7% and the average within-run and total CVs were 3.6% and 5.4%, respectively. The limit of detectability by linear dilution was 20 µg/L, recovery upon dilution was 102% ± 5%, and analytical recovery (of added analyte) was 98% ± 11%. The reference interval (central 90% interval) for chondrex in healthy adults was 25–95 µg/L. Chondrex values for patients with active rheumatoid arthritis or osteoarthritis were significantly greater than in healthy adults, inactive rheumatoid arthritis patients, and diabetes patients (P <0.05). In patients treated with disease-modifying antirheumatic drug therapy, decreasing chondrex values reflected the clinical improvement observed in responders, whereas the values were maintained or increased in nonresponders. In conclusion, chondrex may be a useful marker in the clinical investigation of arthritis.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  M. H. Sohn, J. H. Lee, K. W. Kim, S. W. Kim, S. H. Lee, K.-E. Kim, K. H. Kim, C. G. Lee, J. A. Elias, and M. G. Lee Genetic Variation in the Promoter Region of Chitinase 3-Like 1 Is Associated with Atopy Am. J. Respir. Crit. Care Med., March 15, 2009; 179(6): 449 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Johansen, S. E. Bojesen, A. K. Mylin, R. Frikke-Schmidt, P. A. Price, and B. G. Nordestgaard Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population J. Clin. Oncol., February 1, 2009; 27(4): 572 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Biggar, J. S. Johansen, K. E. Smedby, K. Rostgaard, E. T. Chang, H.-O. Adami, B. Glimelius, D. Molin, S. Hamilton-Dutoit, M. Melbye, et al. Serum YKL-40 and Interleukin 6 Levels in Hodgkin Lymphoma Clin. Cancer Res., November 1, 2008; 14(21): 6974 - 6978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Nielsen, C. Erikstrup, J. S. Johansen, C. P. Fischer, P. Plomgaard, R. Krogh-Madsen, S. Taudorf, B. Lindegaard, and B. K. Pedersen Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes Diabetes, November 1, 2008; 57(11): 3078 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Johansen, T. Lottenburger, H. J. Nielsen, J. E. B. Jensen, M. N. Svendsen, G. Kollerup, and I. J. Christensen Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2603 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Bigg, R. Wait, A. D. Rowan, and T. E. Cawston The Mammalian Chitinase-like Lectin, YKL-40, Binds Specifically to Type I Collagen and Modulates the Rate of Type I Collagen Fibril Formation J. Biol. Chem., July 28, 2006; 281(30): 21082 - 21095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sharif, R. Granell, J. Johansen, S. Clarke, C. Elson, and J. R. Kirwan Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee Rheumatology, May 1, 2006; 45(5): 522 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schmidt, J. S. Johansen, P. Sjoegren, I. J. Christensen, B. S. Sorensen, K. Fode, J. Larsen, and H. von der Maase Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma J. Clin. Oncol., February 10, 2006; 24(5): 798 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Johansen, B. V. Jensen, A. Roslind, D. Nielsen, and P. A. Price Serum YKL-40, A New Prognostic Biomarker in Cancer Patients? Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 194 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. Bergmann, J. S. Johansen, T. W. Klausen, A. K. Mylin, J. S. Kristensen, E. Kjeldsen, and H. E. Johnsen High Serum Concentration of YKL-40 Is Associated with Short Survival in Patients with Acute Myeloid Leukemia Clin. Cancer Res., December 15, 2005; 11(24): 8644 - 8652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bernardi, M. Podswiadek, M. Zaninotto, L. Punzi, and M. Plebani YKL-40 as a Marker of Joint Involvement in Inflammatory Bowel Disease Clin. Chem., October 1, 2003; 49(10): 1685 - 1688. [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Tsark, W. Wang, Y.-C. Teng, D. Arkfeld, G. R. Dodge, and S. Kovats Differential MHC Class II-Mediated Presentation of Rheumatoid Arthritis Autoantigens by Human Dendritic Cells and Macrophages J. Immunol., December 1, 2002; 169(11): 6625 - 6633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ostergaard, J. S. Johansen, T. Benfield, P. A. Price, and J. D. Lundgren YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Purulent Meningitis Clin. Vaccine Immunol., May 1, 2002; 9(3): 598 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Register, C. S. Carlson, and M. R. Adams Serum YKL-40 Is Associated with Osteoarthritis and Atherosclerosis in Nonhuman Primates Clin. Chem., December 1, 2001; 47(12): 2159 - 2161. [Full Text] [PDF]
|
|
|
|
 |
|
 S A YOUNG-MIN, T E CAWSTON, and I D GRIFFITHS Markers of joint destruction: principles, problems, and potential Ann Rheum Dis, June 1, 2001; 60(6): 545a - 548. [Full Text]
|
|
|
|
|
|
E. Gineyts, P. Garnero, and P. D. Delmas Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation Rheumatology, March 1, 2001; 40(3): 315 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Sekine, K Masuko-Hongo, T Matsui, H Asahara, M Takigawa, K Nishioka, and T Kato Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis Ann Rheum Dis, January 1, 2001; 60(1): 49 - 54. [Abstract] [Full Text]
|
|
|
|
|
|
K. Vos, A. M. M. Miltenburg, K. E. van Meijgaarden, M. van den Heuvel, D. G. Elferink, P. J. M. van Galen, R. A. van Hogezand, E. van Vliet-Daskalopoulou, T. H. M. Ottenhoff, F. C. Breedveld, et al. Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions Rheumatology, December 1, 2000; 39(12): 1326 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Conrozier, M-C Carlier, P Mathieu, F Colson, A L Debard, S Richard, H Favret, J Bienvenu, and E Vignon Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study Ann Rheum Dis, October 1, 2000; 59(10): 828 - 831. [Abstract] [Full Text]
|
|
|
|
|
|
K Vos, P Steenbakkers, A M M Miltenburg, E Bos, M W van den Heuvel, R A van Hogezand, R R P de Vries, F C Breedveld, and A M H Boots Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions Ann Rheum Dis, July 1, 2000; 59(7): 544 - 548. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
